The week in pharma: action, reaction and insight – week to October 21, 2022

23 October 2022
tpl-week-in-review-700x466

By Barbara Obstoj-Cardwell. Editor

Licensing and M&A deals featured in last week’s news. First up, MacroGenics signed a collaboration with US biotech major Gilead Sciences last Monday relating to its antibody MGD024 for indications including myeloid leukemia that could earn the company as much as $1.7 billion. Jazz Pharmaceuticals entered a deal with Zymeworks that could cost it over $1.7 billion for rights to the latter’s zanidatamab, an HER2-targeting antibody. Swiss pharma giant Roche signed a license agreement with Austria’s Hookipa Pharma for HB-7001, an arenaviral immunotherapy for KRAS-mutated cancers. Also, Eli Lilly on Tuesday announced it is acquiring US precision medicines company Akouos for up to $610 million, along with its hearing loss treatment candidate AK-OTOF. And AbbVie announced an agreement to acquire UK biotech DJS Antibodies for around $255 million

MacroGenics MGD024 deal provides important cash infusion

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology